{"hands_on_practices": [{"introduction": "Understanding the immunology of granulomas goes beyond textbooks; it involves tangible techniques used in pathology labs to diagnose and characterize disease. This first exercise places you in the role of a pathologist tasked with confirming a T helper type 2 (Th2) response in a tissue sample. By applying fundamental immunological principles, you will design an immunohistochemistry (IHC) panel to visualize the key molecular and cellular players, a critical skill for translating theoretical knowledge into diagnostic practice. [@problem_id:4791158]", "problem": "A liver core biopsy from a patient living in a region endemic for Schistosoma mansoni shows well-formed granulomas centered on helminth eggs, with surrounding fibrosis on routine staining. The clinical question is whether the granulomatous response is skewed toward a T helper type 2 (Th2) immune profile, as would be expected in many helminth infections, and to distinguish this from alternative polarizations. You are asked to select an immunohistochemistry (IHC) panel that best operationalizes and tests the Th2 hypothesis in tissue, based on fundamental immunology. As the fundamental base, use the following well-tested facts: naive CD4 T cells polarize under cytokine cues; interleukin-4 ($\\text{IL-4}$) engagement activates signal transducer and activator of transcription 6 (STAT6), inducing GATA binding protein 3 (GATA3) and driving a Th2 program with effector cytokines interleukin-4 ($\\text{IL-4}$), interleukin-5 ($\\text{IL-5}$), and interleukin-13 ($\\text{IL-13}$). Th2 cytokines promote alternative (M2) macrophage activation (for example, with mannose receptor CD206 expression) and recruit eosinophils; interleukin-13 ($\\text{IL-13}$) and transforming growth factor beta ($\\text{TGF-}\\beta$) stimulate fibroblasts, increasing collagen type I and type III deposition. In contrast, a T helper type 1 (Th1) response is characterized by T-box transcription factor TBX21 (T-bet), interferon-gamma ($\\text{IFN-}\\gamma$), inducible nitric oxide synthase (iNOS), and classically activated macrophages, while T helper type 17 (Th17) is characterized by RAR-related orphan receptor gamma T (ROR$\\gamma$T) and interleukin-17A ($\\text{IL-17A}$), and regulatory T cells (Treg) by forkhead box P3 (FOXP3) and interleukin-10 ($\\text{IL-10}$).\n\nWhich of the following IHC panels most specifically identifies and justifies a Th2-skewed granulomatous response in this context?\n\nA. Anti-GATA3, anti-$\\text{IL-4}$, anti-$\\text{IL-13}$, anti-CD206, anti-collagen type I and type III.\n\nB. Anti-T-bet, anti-$\\text{IFN-}\\gamma$, anti-iNOS, anti-HLA-DR (human leukocyte antigen - DR isotype), anti-collagen type I and type III.\n\nC. Anti-GATA3, anti-$\\text{IL-5}$, anti-major basic protein (MBP; eosinophil granule), anti-CD163 (hemoglobin scavenger receptor), anti-collagen type I and type III.\n\nD. Anti-ROR$\\gamma$T, anti-$\\text{IL-17A}$, anti-neutrophil elastase, anti-myeloperoxidase (MPO), anti-collagen type I.\n\nE. Anti-FOXP3, anti-$\\text{IL-10}$, anti-$\\text{TGF-}\\beta$, anti-programmed cell death protein 1 (PD-1), reticulin stain.", "solution": "The problem presents a clinical-pathological scenario of hepatic schistosomiasis and asks for the selection of an immunohistochemistry (IHC) panel that best validates the hypothesis of a T helper type 2 (Th2) skewed immune response. The problem provides a set of immunological facts to serve as the basis for this decision.\n\n**Problem Validation**\n\nFirst, the validity of the problem statement is assessed.\n\n**Step 1: Extract Givens**\n-   **Clinical Context**: Patient from a *Schistosoma mansoni* endemic area.\n-   **Histopathology**: Liver biopsy shows well-formed granulomas centered on helminth eggs, with surrounding fibrosis.\n-   **Central Question**: Is the granulomatous response skewed toward a Th2 profile?\n-   **Task**: Select the IHC panel that best operationalizes and tests the Th2 hypothesis.\n-   **Fundamental Principles Provided**:\n    1.  Th2 polarization is driven by interleukin-4 ($\\text{IL-4}$), which activates STAT6 and induces the master transcription factor GATA binding protein 3 (GATA3).\n    2.  Th2 effector cytokines are $\\text{IL-4}$, interleukin-5 ($\\text{IL-5}$), and interleukin-13 ($\\text{IL-13}$).\n    3.  Th2 cytokines promote alternative (M2) macrophage activation, exemplified by mannose receptor CD206 expression.\n    4.  Th2 cytokines recruit eosinophils.\n    5.  $\\text{IL-13}$ and transforming growth factor beta ($\\text{TGF-}\\beta$) stimulate fibroblasts, increasing collagen type I and type III deposition.\n    6.  Distinct markers for other T helper subsets are provided for contrast: Th1 (T-bet, $\\text{IFN-}\\gamma$), Th17 (ROR$\\gamma$T, $\\text{IL-17A}$), and Treg (FOXP3, $\\text{IL-10}$).\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding**: The problem is scientifically sound. The described immunopathology of schistosomiasis, characterized by an egg-induced, Th2-dominated granulomatous response leading to hepatic fibrosis (Symmers' pipe-stem fibrosis), is a canonical example in medical parasitology and immunology. The molecular pathways ($\\text{IL-4}$/STAT6/GATA3 axis), effector cytokines ($\\text{IL-4}$, $\\text{IL-5}$, $\\text{IL-13}$), and downstream consequences (M2 macrophage activation, eosinophilia, collagen deposition) are all well-established scientific facts.\n-   **Well-Posedness**: The problem is well-posed. It asks for the *best* choice among a set of options to test a specific, defined hypothesis using a standard laboratory technique (IHC), based on a provided set of axioms. A single best answer can be logically deduced.\n-   **Objectivity**: The language is technical and objective, devoid of subjective or ambiguous terminology.\n\n**Step 3: Verdict and Action**\n-   The problem statement is valid. It is scientifically grounded, well-posed, objective, and contains sufficient information to derive a solution. The solution process may proceed.\n\n**Derivation of the Solution**\n\nThe objective is to construct an ideal IHC panel based on the provided principles to identify a Th2-skewed response and then to compare this ideal panel with the given options.\n\nAn ideal panel would confirm several key aspects of the Th2 pathway:\n1.  **Lineage Commitment**: Detection of the master transcription factor, **GATA3**, in the nuclei of T lymphocytes within the granuloma.\n2.  **Effector Function (Cytokines)**: Detection of the signature Th2 cytokines. The provided facts highlight **$\\text{IL-4}$** (driving differentiation) and **$\\text{IL-13}$** (driving fibrosis) as particularly crucial.\n3.  **Downstream Cellular Effects**:\n    a.  **Macrophage Polarization**: Detection of alternatively activated (M2) macrophages using the explicitly mentioned marker, **CD206**.\n    b.  **Fibrosis**: Confirmation of the specific collagen types involved in the pathology, namely **collagen type I and type III**.\n\nCombining these elements gives an ideal panel: Anti-GATA3, Anti-$\\text{IL-4}$, Anti-$\\text{IL-13}$, Anti-CD206, and Anti-collagen (I/III). This panel comprehensively interrogates the Th2 response from its transcriptional origin to its pathological endpoint.\n\n**Evaluation of Options**\n\n**A. Anti-GATA3, anti-$\\text{IL-4}$, anti-$\\text{IL-13}$, anti-CD206, anti-collagen type I and type III.**\n-   **Anti-GATA3**: Correctly identifies the Th2 master transcription factor.\n-   **Anti-$\\text{IL-4}$**: Correctly identifies the principal cytokine that drives Th2 differentiation.\n-   **Anti-$\\text{IL-13}$**: Correctly identifies the principal cytokine responsible for the fibrotic pathology in this context.\n-   **Anti-CD206**: Correctly identifies M2 macrophages, using the specific example marker provided in the problem statement.\n-   **Anti-collagen type I and type III**: Correctly identifies the extracellular matrix components pathognomonic of the Th2-driven fibrotic response.\nThis panel aligns perfectly with the multi-level validation strategy derived from the problem's first principles.\n**Verdict: Correct.**\n\n**B. Anti-T-bet, anti-$\\text{IFN-}\\gamma$, anti-iNOS, anti-HLA-DR (human leukocyte antigen - DR isotype), anti-collagen type I and type III.**\n-   This panel is designed to identify a **Th1** response. Anti-T-bet (Th1 master factor), anti-$\\text{IFN-}\\gamma$ (Th1 cytokine), and anti-iNOS (marker of classically activated M1 macrophages) are all hallmarks of Th1 polarization. Anti-HLA-DR is a general marker for antigen-presenting cells and is not specific to any T helper subset skew. This panel tests the null hypothesis, but it does not identify the Th2 response itself.\n**Verdict: Incorrect.**\n\n**C. Anti-GATA3, anti-$\\text{IL-5}$, anti-major basic protein (MBP; eosinophil granule), anti-CD163 (hemoglobin scavenger receptor), anti-collagen type I and type III.**\n-   This panel is also a strong candidate for identifying a Th2 response. It includes the master regulator (GATA3), a key cytokine/cellular axis ($\\text{IL-5}$/eosinophils via MBP), another M2 macrophage marker (CD163), and fibrosis markers. However, it omits $\\text{IL-4}$ and $\\text{IL-13}$, which are explicitly cited in the problem as the fundamental driver of Th2 polarization and the key mediator of fibrosis, respectively. While CD163 is a valid M2 marker, the problem text specifically provided CD206 as the example. Panel A is more comprehensive because it includes the initiating cytokine ($\\text{IL-4}$) and the primary fibrotic cytokine ($\\text{IL-13}$), making it a more direct and complete test of the provided hypothesis.\n**Verdict: Incorrect.** This panel is plausible but less specific and comprehensive than A according to the problem's own stated facts.\n\n**D. Anti-ROR$\\gamma$T, anti-$\\text{IL-17A}$, anti-neutrophil elastase, anti-myeloperoxidase (MPO), anti-collagen type I.**\n-   This panel is designed to identify a **Th17** response. Anti-ROR$\\gamma$T (Th17 master factor), anti-$\\text{IL-17A}$ (Th17 cytokine), and markers for neutrophils (neutrophil elastase, MPO), the primary effectors of Th17 immunity, are all characteristic of this lineage. This is an incorrect polarization for the given pathology.\n**Verdict: Incorrect.**\n\n**E. Anti-FOXP3, anti-$\\text{IL-10}$, anti-$\\text{TGF-}\\beta$, anti-programmed cell death protein 1 (PD-1), reticulin stain.**\n-   This panel is designed to identify a **Treg** (regulatory T cell) and/or T cell exhaustion response. Anti-FOXP3 (Treg master factor) and anti-$\\text{IL-10}$ (Treg cytokine) are a giveaway. Anti-PD-1 is a marker of T cell exhaustion, common in chronic infections. While Tregs and exhaustion are indeed features of chronic schistosomiasis, this panel does not test for the primary pro-inflammatory, granuloma-forming Th2 response in question. Reticulin stains for collagen type III, but the panel's focus is on regulation/exhaustion.\n**Verdict: Incorrect.**\n\n**Conclusion**\nOption A provides the most specific and comprehensive set of markers to test the Th2 hypothesis as it is defined by the fundamental principles laid out in the problem statement. It covers the transcriptional control (GATA3), the key initiating and pathological cytokines ($\\text{IL-4}$, $\\text{IL-13}$), the downstream macrophage polarization (CD206), and the ultimate tissue pathology (collagen I and III).", "answer": "$$\\boxed{A}$$", "id": "4791158"}, {"introduction": "Once we can identify the key cells of a granuloma, such as the eosinophils characteristic of a Th2 response, the next logical step is to understand the forces that govern their numbers. This practice introduces a simple but powerful mathematical model to explore the concept of a steady state, where the recruitment of eosinophils driven by cytokines like Interleukin-5 (IL-5) is perfectly balanced by their natural loss. This exercise provides a quantitative foundation for understanding how the immunological environment dictates the cellular composition of a granuloma. [@problem_id:4791118]", "problem": "A patient with chronic Schistosoma mansoni egg deposition in the intestinal wall develops perioval granulomas characterized by dense eosinophilic infiltrates. In granulomatous inflammation driven by helminth antigens, Interleukin-5 (IL-5) produced by T helper type 2 (Th2) cells is a principal cytokine promoting eosinophil recruitment from the bone marrow and prolonging eosinophil survival within tissues. Consider a minimal mass-balance model for the eosinophil count in tissue, denoted by $E(t)$, where recruitment is proportional to the IL-5 concentration and loss is first-order due to apoptosis or egress:\n$$\\frac{dE}{dt}=\\alpha\\,L-\\beta\\,E.$$\nHere, $L$ is the IL-5 level (assumed constant over the timescale of interest), $\\alpha$ is the recruitment efficacy per unit IL-5, and $\\beta$ is the first-order loss rate constant. Starting from the core definitions of steady-state in dynamical systems and the biological assumption that recruitment increases with IL-5 while loss is proportional to the current eosinophil pool, derive the steady-state eosinophil count $E^{*}$ as a function of $L$, $\\alpha$, and $\\beta$. Then, compute the numerical value of $E^{*}$ for an IL-5 level $L=20$ pg mL$^{-1}$, recruitment parameter $\\alpha=15$ cells $\\mu$L$^{-1}$ day$^{-1}$ (pg mL$^{-1}$)$^{-1}$, and loss parameter $\\beta=0.60$ day$^{-1}$. Round your final numerical answer to three significant figures and express it in cells $\\mu$L$^{-1}$. In your reasoning, explain the biological meaning of $\\alpha$ and $\\beta$ in helminth-associated granulomatous inflammation without using any pre-derived shortcut formulas.", "solution": "Granulomatous inflammation in parasitic infections such as schistosomiasis emerges from persistent antigenic stimulation, notably schistosome ova lodged in tissues. T helper type 2 (Th2) responses predominate, with cytokines including Interleukin-5 (IL-5) driving eosinophil proliferation, differentiation, recruitment, and survival. A minimal dynamical system for eosinophils in tissue balances influx (recruitment) and efflux (loss). The recruitment rate should increase with the concentration of IL-5, reflecting cytokine-mediated signaling, while loss typically follows first-order kinetics if the probability of apoptosis or egress is proportional to the number present.\n\nGiven the ordinary differential equation\n$$\\frac{dE}{dt}=\\alpha\\,L-\\beta\\,E,$$\nthe steady-state $E^{*}$ is defined by the condition of no net change:\n$$\\frac{dE}{dt}\\Big|_{E=E^{*}}=0.$$\nSetting the right-hand side to zero yields\n$$0=\\alpha\\,L-\\beta\\,E^{*}.$$\nSolving algebraically for $E^{*}$ gives\n$$\\beta\\,E^{*}=\\alpha\\,L \\quad \\Rightarrow \\quad E^{*}=\\frac{\\alpha}{\\beta}\\,L.$$\n\nBefore computing, we examine units to ensure scientific consistency. The parameter $\\alpha$ has units of cells $\\mu$L$^{-1}$ day$^{-1}$ (pg mL$^{-1}$)$^{-1}$, $L$ has units of pg mL$^{-1}$, and $\\beta$ has units of day$^{-1}$. Thus,\n$$\\frac{\\alpha}{\\beta}\\,L \\ \\text{has units} \\ \\frac{\\text{cells}\\ \\mu\\text{L}^{-1}\\ \\text{day}^{-1}\\ (\\text{pg mL}^{-1})^{-1}}{\\text{day}^{-1}}\\times \\text{pg mL}^{-1}=\\text{cells}\\ \\mu\\text{L}^{-1},$$\nwhich matches the desired unit for eosinophil count density.\n\nNow substitute the given values symbolically and then numerically:\n$$E^{*}=\\frac{\\alpha}{\\beta}\\,L=\\frac{15}{0.60}\\times 20.$$\nCompute the ratio and product:\n$$\\frac{15}{0.60}=25,$$\nso\n$$E^{*}=25\\times 20=500.$$\nRounded to three significant figures, $500$ can be represented as $5.00\\times 10^{2}$, and the unit is cells $\\mu$L$^{-1}$.\n\nInterpretation of parameters in helminth-associated granulomatous inflammation:\n- $\\alpha$ quantifies the efficacy of IL-5 in recruiting and sustaining eosinophils per unit cytokine concentration. A larger $\\alpha$ reflects stronger IL-5 signaling (for example, robust Th2 activation or heightened marrow responsiveness), leading to greater eosinophil influx per pg mL$^{-1}$ of IL-5.\n- $\\beta$ is the first-order loss rate constant capturing eosinophil removal via apoptosis, tissue egress, or consumption in effector functions. A larger $\\beta$ indicates faster turnover, reducing the steady-state pool for a given IL-5 level. In helminth infections that promote eosinophil survival signals, $\\beta$ may be relatively reduced, contributing to eosinophilia in granulomas.\n\nTherefore, the derived expression $E^{*}=(\\alpha/\\beta)L$ describes how the steady-state eosinophil burden in granulomatous tissue scales directly with IL-5 signaling strength and inversely with eosinophil turnover kinetics, consistent with known Th2-driven eosinophilia in parasitic granulomas. The numerical value under the provided parameters is $5.00\\times 10^{2}$ cells $\\mu$L$^{-1}$.", "answer": "$$\\boxed{5.00 \\times 10^{2}}$$", "id": "4791118"}, {"introduction": "While steady-state models offer a snapshot of equilibrium, many disease processes, like the development of fibrosis, are fundamentally dynamic. This final practice elevates our analysis by modeling the change in fibrosis over time in response to a transient pro-fibrotic signal. By solving a differential equation, you will derive an expression for how collagen accumulates and degrades, providing insight into the kinetics of tissue scarring—a major clinical consequence of chronic granulomatous inflammation. [@problem_id:4791156]", "problem": "Granulomatous inflammation surrounding Schistosoma mansoni eggs in the liver is characterized by a local surge in Transforming Growth Factor beta (TGF-β), a pro-fibrotic cytokine that activates fibroblasts to synthesize collagen. Consider a simplified mechanistic description of fibrosis accumulation in hepatic tissue, where the fibrosis index $F(t)$ (defined as collagen mass per unit tissue mass) evolves according to the ordinary differential equation\n$$\\frac{dF}{dt}=\\gamma T(t)-\\delta F(t),$$\nwith $\\gamma>0$ the collagen synthesis rate per unit TGF-β concentration, $\\delta>0$ the first-order collagen turnover rate, and $T(t)$ the local TGF-β concentration. Assume that following egg antigen exposure at $t=0$, the TGF-β concentration decays exponentially according to\n$$T(t)=T_{0}\\exp(-\\alpha t),$$\nwith $T_{0}>0$ the peak concentration and $\\alpha>0$ the decay constant, and that $F(0)=F_{0}$ is the pre-existing fibrosis.\n\nUsing only the premises that (i) collagen synthesis is proportional to TGF-β concentration and (ii) collagen turnover is first-order, derive from first principles an analytic expression for the fibrosis index $F(\\tau)$ at a fixed time $\\tau>0$. Then, compute the cumulative collagen deposition over the same interval, defined as\n$$D(\\tau)=\\int_{0}^{\\tau}\\gamma T(s)\\,ds.$$\nAssume $\\alpha\\neq\\delta$. Express both $F(\\tau)$ and $D(\\tau)$ in milligrams of collagen per gram of tissue (mg/g). Your final answer must be given as closed-form expressions in terms of $F_{0}$, $T_{0}$, $\\gamma$, $\\delta$, $\\alpha$, and $\\tau$, and must not contain any inequalities or equations. No numerical evaluation or rounding is required.", "solution": "The problem is subjected to validation before proceeding with a solution.\n\n### Step 1: Extract Givens\n-   **Governing Equation:** The fibrosis index, $F(t)$, evolves according to the ordinary differential equation $\\frac{dF}{dt}=\\gamma T(t)-\\delta F(t)$.\n-   **Parameters:**\n    -   $\\gamma > 0$: collagen synthesis rate per unit TGF-$\\beta$ concentration.\n    -   $\\delta > 0$: first-order collagen turnover rate.\n-   **Forcing Function:** The TGF-$\\beta$ concentration is given by $T(t)=T_{0}\\exp(-\\alpha t)$.\n    -   $T_{0} > 0$: peak concentration at $t=0$.\n    -   $\\alpha > 0$: decay constant.\n-   **Initial Condition:** The initial fibrosis index is $F(0)=F_{0}$.\n-   **Constraint:** It is assumed that $\\alpha \\neq \\delta$.\n-   **Objective 1:** Derive an analytic expression for the fibrosis index $F(\\tau)$ at a fixed time $\\tau > 0$.\n-   **Objective 2:** Compute the cumulative collagen deposition over the same interval, defined as $D(\\tau)=\\int_{0}^{\\tau}\\gamma T(s)\\,ds$.\n-   **Premises:** (i) collagen synthesis is proportional to TGF-$\\beta$ concentration, and (ii) collagen turnover is first-order. These are the explicit foundations for the terms $\\gamma T(t)$ and $-\\delta F(t)$ respectively.\n\n### Step 2: Validate Using Extracted Givens\nThe problem presents a simplified, yet mechanistically plausible, mathematical model of a biological process.\n-   **Scientifically Grounded:** The model is based on established principles in systems biology and pathology. The roles of TGF-$\\beta$ in fibrosis and the use of first-order linear ordinary differential equations to model such kinetic processes are standard and scientifically sound. The problem does not violate any fundamental principles.\n-   **Well-Posed:** The problem is a well-posed initial value problem for a first-order linear ordinary differential equation. It provides the equation, a well-defined forcing function, and a necessary initial condition. The constraint $\\alpha \\neq \\delta$ is explicitly stated, which prevents the denominator in the standard particular solution from becoming zero, ensuring a unique and well-defined solution exists.\n-   **Objective and Complete:** The problem is stated in precise, objective language. All necessary symbolic constants and functions for deriving a closed-form solution are provided. The problem is self-contained and free of contradictions.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is a clear, self-contained, and scientifically grounded exercise in solving a first-order linear ODE. A full solution will be derived.\n\n### Derivation of the Fibrosis Index $F(\\tau)$\n\nThe evolution of the fibrosis index $F(t)$ is governed by the first-order linear ordinary differential equation:\n$$\n\\frac{dF}{dt} = \\gamma T(t) - \\delta F(t)\n$$\nSubstituting the given expression for $T(t) = T_{0}\\exp(-\\alpha t)$, we obtain:\n$$\n\\frac{dF}{dt} = \\gamma T_{0}\\exp(-\\alpha t) - \\delta F(t)\n$$\nThis equation can be rearranged into the standard form for a first-order linear ODE, $\\frac{dy}{dx} + P(x)y = Q(x)$:\n$$\n\\frac{dF}{dt} + \\delta F(t) = \\gamma T_{0}\\exp(-\\alpha t)\n$$\nTo solve this equation, we use the method of integrating factors. The integrating factor, $I(t)$, is given by:\n$$\nI(t) = \\exp\\left(\\int \\delta \\,dt\\right) = \\exp(\\delta t)\n$$\nMultiplying the standard form of the ODE by the integrating factor $I(t)$:\n$$\n\\exp(\\delta t)\\frac{dF}{dt} + \\delta \\exp(\\delta t)F(t) = \\gamma T_{0}\\exp(-\\alpha t)\\exp(\\delta t)\n$$\nThe left-hand side of this equation is the derivative of the product $F(t)I(t)$:\n$$\n\\frac{d}{dt}\\left(F(t)\\exp(\\delta t)\\right) = \\gamma T_{0}\\exp((\\delta - \\alpha)t)\n$$\nWe now integrate both sides with respect to $t$:\n$$\n\\int \\frac{d}{dt}\\left(F(t)\\exp(\\delta t)\\right) dt = \\int \\gamma T_{0}\\exp((\\delta - \\alpha)t) dt\n$$\n$$\nF(t)\\exp(\\delta t) = \\gamma T_{0} \\int \\exp((\\delta - \\alpha)t) dt\n$$\nSince it is given that $\\alpha \\neq \\delta$, the term $\\delta - \\alpha$ is non-zero. The integration yields:\n$$\nF(t)\\exp(\\delta t) = \\gamma T_{0} \\frac{\\exp((\\delta - \\alpha)t)}{\\delta - \\alpha} + C\n$$\nwhere $C$ is the constant of integration. To find the general solution for $F(t)$, we divide by the integrating factor $\\exp(\\delta t)$:\n$$\nF(t) = \\frac{\\gamma T_{0}}{\\delta - \\alpha} \\exp(-\\alpha t) + C \\exp(-\\delta t)\n$$\nThe constant $C$ is determined by applying the initial condition $F(0) = F_{0}$:\n$$\nF(0) = F_{0} = \\frac{\\gamma T_{0}}{\\delta - \\alpha} \\exp(0) + C \\exp(0)\n$$\n$$\nF_{0} = \\frac{\\gamma T_{0}}{\\delta - \\alpha} + C\n$$\nSolving for $C$:\n$$\nC = F_{0} - \\frac{\\gamma T_{0}}{\\delta - \\alpha}\n$$\nSubstituting this expression for $C$ back into the general solution for $F(t)$:\n$$\nF(t) = \\frac{\\gamma T_{0}}{\\delta - \\alpha} \\exp(-\\alpha t) + \\left(F_{0} - \\frac{\\gamma T_{0}}{\\delta - \\alpha}\\right) \\exp(-\\delta t)\n$$\nThis can be rearranged by grouping terms:\n$$\nF(t) = F_{0} \\exp(-\\delta t) + \\frac{\\gamma T_{0}}{\\delta - \\alpha} (\\exp(-\\alpha t) - \\exp(-\\delta t))\n$$\nThe problem asks for the fibrosis index at a specific time $\\tau > 0$. We replace $t$ with $\\tau$ to obtain the final expression for $F(\\tau)$:\n$$\nF(\\tau) = F_{0} \\exp(-\\delta \\tau) + \\frac{\\gamma T_{0}}{\\delta - \\alpha} (\\exp(-\\alpha \\tau) - \\exp(-\\delta \\tau))\n$$\nThis expression gives the fibrosis index as a function of the initial fibrosis, the parameters governing synthesis and decay, and time. The first term represents the decay of the initial fibrosis, while the second term represents the net accumulation due to the transient TGF-$\\beta$ signal.\n\n### Calculation of Cumulative Collagen Deposition $D(\\tau)$\n\nThe cumulative collagen deposition, $D(\\tau)$, is defined as the time integral of the synthesis term, $\\gamma T(s)$, from $s=0$ to $s=\\tau$:\n$$\nD(\\tau) = \\int_{0}^{\\tau} \\gamma T(s) \\,ds\n$$\nSubstituting the expression for $T(s)=T_{0}\\exp(-\\alpha s)$:\n$$\nD(\\tau) = \\int_{0}^{\\tau} \\gamma T_{0} \\exp(-\\alpha s) \\,ds\n$$\nSince $\\gamma$ and $T_{0}$ are constants, they can be factored out of the integral:\n$$\nD(\\tau) = \\gamma T_{0} \\int_{0}^{\\tau} \\exp(-\\alpha s) \\,ds\n$$\nWe perform the definite integration:\n$$\nD(\\tau) = \\gamma T_{0} \\left[ -\\frac{1}{\\alpha} \\exp(-\\alpha s) \\right]_{0}^{\\tau}\n$$\n$$\nD(\\tau) = -\\frac{\\gamma T_{0}}{\\alpha} \\left[ \\exp(-\\alpha \\tau) - \\exp(-\\alpha \\cdot 0) \\right]\n$$\n$$\nD(\\tau) = -\\frac{\\gamma T_{0}}{\\alpha} (\\exp(-\\alpha \\tau) - 1)\n$$\nDistributing the negative sign gives the final expression for $D(\\tau)$:\n$$\nD(\\tau) = \\frac{\\gamma T_{0}}{\\alpha} (1 - \\exp(-\\alpha \\tau))\n$$\nThis expression represents the total amount of collagen synthesized (per unit tissue mass) over the interval $[0, \\tau]$ in response to the TGF-$\\beta$ signal. The units for both $F(\\tau)$ and $D(\\tau)$ are given as milligrams of collagen per gram of tissue (mg/g), which is consistent with the definition of the fibrosis index as a mass-per-mass quantity. The derived symbolic expressions are the required answers.", "answer": "$$\n\\boxed{\\begin{pmatrix} F_{0} \\exp(-\\delta \\tau) + \\frac{\\gamma T_{0}}{\\delta - \\alpha} (\\exp(-\\alpha \\tau) - \\exp(-\\delta \\tau)) & \\frac{\\gamma T_{0}}{\\alpha} (1 - \\exp(-\\alpha \\tau)) \\end{pmatrix}}\n$$", "id": "4791156"}]}